International uniform response criteria for multiple myeloma

By B. Durie, J. Harousseau, J. Miguel, J. Bladé, B. Barlogie, K. Anderson, M. Gertz, M. Dimopoulos, J. Westin, P. Sonneveld and 21 more. Leukemia, 2006

2,475 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/7bb3c42f839e7ad0c232489c7aa8049d366b0623

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. S. Rajkumar
2. Jennifer N. Brudno
3. J. Kochenderfer
4. S. Swerdlow
5. J. Adams

In Molecular Biology

1. S. Rajkumar
2. P. Richardson
3. T. Hideshima
4. J. Adams

In Oncology

1. S. Rajkumar
2. J. Kochenderfer
3. Jennifer N. Brudno
4. J. Adams
5. J. Fishman

Citations in the corpus

• Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. (2011, methodology): “Clinical relapse will be defined using the definition of clinical relapse in the IMWG criteria.(7) In the IMWG criteria clinical relapse is defined as requiring one or more of the following direct indicators of increasing disease and/or end organ dysfunction (CRAB features) that are felt related to ”
• Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010, methodology): “The rate of very good partial response (VGPR) or better was also determined, reflecting the recent introduction of the International Uniform Response Criteria.(21)”
• Continuous lenalidomide treatment for newly diagnosed multiple myeloma. (2012, neutral): “Infection* 14 (9) 1 (1) 20 (13) 3 (2) 11 (7) 0”
• T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. (2018, methodology): “MM response assessment was conducted according to the International Uniform Response Criteria for Multiple Myeloma.(32) Cytokine-release syndrome (CRS) was graded as described.”
• The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. (2011, background): “Some myeloma cooperative groups prefer a cutoff of 30% bone marrow plasma cells for a diagnosis of PCM in a patient with amyloidosis.(14)”